Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/23/17
04/23
04:55
04/23/17
04:55

European Association for the Study of Liver

International Liver Congress 2017 is being held in Amsterdam, The Netherlands on April 19-23.

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

ABBV AbbVie
$63.82

0.04 (0.06%)

04/17/17
JEFF
04/17/17
NO CHANGE
Target $97
JEFF
Buy
Jefferies sees Lilly trading down 5% on baricitinib CRL
Jefferies analyst Jeffrey Holford expects Eli Lilly (LLY) to trade down around 5% after the company and Incyte (INCY) received a complete response letter from the FDA for baricitinib. A significant delay to the U.S. approval of baricitinib could hit Lilly's mid-term earnings and valuation by up to 8%-10%, Holford tells investors in a research note. He notes, however, that the cause or extent of the delay is unclear at this point. Holford keeps a Buy rating on Lilly with a $97 price target. The analyst views the baricitinib CRL as a positive for AbbVie's (ABBV) "best in class" JAK inhibitor, ABT-4494. A delay to baricitinib could result in ABT-494 reaching the U.S. market before baricitinib, the analyst contends.
04/20/17
LEER
04/20/17
NO CHANGE
Target $71
LEER
Market Perform
AbbVie veliparib not competitive with other products, says Leerink
Leerink analyst Geoffrey Porges notes that AbbVie announced failed top-line results for its PARP inhibitor veliparib in combination with chemotherapy for metastatic squamous NSCLC and early TNBC. While two disappointing trials would not normally completely doom a program, the analyst says that the lack of effect confirms his view that veliparib has limited activity and is not competitive with other products in this class. For this reason, Porges is taking the probability of success of the program to zero. The analyst reiterated a Market Perform rating on the stock and lowered his price target on the shares to $71 from $72.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $90
JEFF
Buy
AbbVie cancer drug failure should have little impact, says Jefferies
Jefferies analyst Jeffrey Holford expects the Phase III failure of veliparib to have little impact on AbbVie shares. The analyst says expectations were low and that the drug accounted for less than 1% of his mid-term revenues estimates. He keeps a Buy rating on AbbVie with a $90 price target.
04/20/17
RHCO
04/20/17
NO CHANGE
RHCO
Tesaro has no negative read through from AbbVie failure, says SunTrust
SunTrust analyst Peter Lawson says that there is "no impact" on Tesaro's (TSRO) niraparib from the failure of AbbVie's (ABBV) PARP inhibitor, veliparib, in triple negative breast cancer and lung cancer. The analyst believes that niraparib could be more effective than veliparib. Additionally, he notes that during its trial veliparib was used in combination with chemotherapy, while niraparib will be combined with Merck's (MRK) Keytruda for its trial. He thinks that the pairing with Keytruda will result in more effective treatment. The analyst keeps a $235 price target and a Buy rating on Tesaro.
ALXN Alexion
$116.82

-1.9 (-1.60%)

03/29/17
UBSW
03/29/17
INITIATION
Target $138
UBSW
Buy
Alexion initiated with a Buy at UBS
UBS analyst Martin Auster initiated Alexion with a Buy rating and $138 price target.
03/30/17
03/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sunoco (SUN) initiated with a Sell at Goldman. 2. CyberArk (CYBR) initiated with an Equal Weight at Morgan Stanley. 3. Humana (HUM) reinstated with an Outperform at Oppenheimer. 4. Qualys (QLYS) initiated with an Overweight at Morgan Stanley. 5. Alexion (ALXN), AveXis (AVXS), and Spark Therapeutics (ONCE) were initiated with a Buy at UBS, while Alnylam (ALNY) and BioMarin (BMRN) were initiated with a Neutral, and United Therapeutics (UTHR) was initiated with a Sell. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/17
RAJA
03/27/17
NO CHANGE
RAJA
Strong Buy
Alexion execution should improve with new CEO, says Raymond James
Raymond James analyst Christopher Raymond said the appointment of Ludwig Hantson, PdD as Alexion's new CEO will result in less drama, and more execution going forward. Raymond said some investors may be disappointed in that this may reduce the likelihood of a takeout, but he never saw this has a highly likely scenario. The analyst believes a turnaround is in the making and remains a buyer as this plays out given strong volume-driven growth from commercial products and upcoming catalysts, including Soliris MG approval. Raymond rates Alexion a Strong Buy.
03/13/17
LEER
03/13/17
NO CHANGE
Target $208
LEER
Outperform
Alexion price target lowered to $208 from $217 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Alexion to $208 from $217 after the company disclosed the sBLA for Soliris in myasthenia gravis was accepted by the FDA with a PDUFA date of October 23, 2017, and clarified that the timing for its neuromyelitis optica Phase 3 results will be 2018, not 2017. The analyst noted that both updates delay the launch and ramp of revenues for these indications in his model, as he previously assumed myasthenia gravis launched in mid-2017 and neuromyelitis optica launched in 2018. He reiterates an Outperform rating on the shares.
BAX Baxter
$52.88

-0.01 (-0.02%)

04/10/17
JEFF
04/10/17
NO CHANGE
JEFF
Akorn takeout at $36-$40/share not unreasonable, says Jefferies
With Fresenius (FSNUY) and Akorn (AKRX) confirming buyout talks, Jefferies analyst Chris Cooper says a price for Akorn at 4.5 to 5 times sales, or $36 to $40 per share, is not unreasonable based on comp deals. The analyst notes Baxter's December 2016 acquisition of Claris was done at 6.3 times sales. Akorn closed Friday up 18% to $29.77 after Bloomberg broke news of the merger talks.
04/04/17
04/04/17
UPGRADE
Target $64

Outperform
Baxter upgraded to Outperform at Leerink
As previously reported, Leerink analyst Danielle Antalffy upgraded Baxter to Outperform from Market Perform as she believes post-spin "new" turnaround story still has room for significant upside given six consecutive "beat and raise" EPS quarters, operating margin already tracking ahead of management's current long-range plan, and increasingly strong free cash flow generation. While the analyst believes the incremental margin upside potential is already priced in, the magnitude of sales growth reacceleration and potential free cash flow generation is still underappreciated. Antalffy also raised her price target on the shares to $64 from $54.
04/04/17
LEER
04/04/17
UPGRADE
LEER
Outperform
Baxter upgraded to Outperform from Market Perform at Leerink
10/13/16
10/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Buy at Jefferies. 2. eBay (EBAY) and Etsy (ETSY) coverage assumed with a Neutral at Wedbush. 3. Five Below (FIVE) and Dollar Tree (DLTR) were initiated with an Overweight at KeyBanc while the firm initiated Dollar General (DG) with a Sector Weight. 4. Baxter (BAX) initiated with an Outperform at Wells Fargo. 5. Symantec (SYMC) initiated with an Outperform at FBN Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CPHD Cepheid

09/07/16
BTIG
09/07/16
DOWNGRADE
BTIG
Neutral
Cepheid downgraded to Neutral from Buy at BTIG
Cepheid (CPHD) is being acquired by Danaher (DHR) for $53 per share in cash
09/07/16
BERN
09/07/16
NO CHANGE
BERN
Danaher acquisition should be positive over the mid to long-term, says Bernstein
After Danaher (DHR) agreed to buy Cepheid (CPHD), Bernstein analyst Steven Winoker says that the deal was expensive. However, the analyst says that Cepheid has high recurring revenue, fast growth, and strong synergies with Danaher. Winoker thinks that the deal leaves Danaher well-positioned for growth over the medium to longer term. He keeps a $92 price target and Outperform rating on the stock.
09/08/16
SBSH
09/08/16
DOWNGRADE
Target $53
SBSH
Neutral
Cepheid downgraded to Neutral from Buy at Citi
Citi analyst Daniel Arias downgraded Cepheid (CPHD) to Neutral following the $53 per share takeout bid from Danaher (DHR). The analyst sees the likelihood of a competing bid as low.
09/12/16
BARD
09/12/16
DOWNGRADE
BARD
Neutral
Cepheid downgraded to Neutral from Outperform at Baird
Cepheid (CPHD) is being acquired by Danaher (DHR) for $53 per share in cash
GALT Galectin Therapeutics
$3.09

-0.14 (-4.33%)

09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
FBRC
10/03/16
DOWNGRADE
Target $2
FBRC
Market Perform
Galectin Therapeutics downgraded to Market Perform from Outperform at FBR Capital
FBR Capital analyst Vernon Bernardino downgraded Galectin Therapeutics to Market Perfrom and lowered its price target to $2 from $12 following the failure of NASH-FX to meet its primary and secondary endpoints. The study was one of two ongoing Phase II clinical trials to evaluate GALTb's galectin-3 inhibitor drug candidate, GRMD-02, in patients with non-alcoholic steatohepatitis.
03/30/17
HCWC
03/30/17
UPGRADE
Target $3.5
HCWC
Buy
Galectin Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Ed Arce upgraded Galectin Therapeutics to Buy citing a more positive view of the therapeutic potential of the mechanism of galectin-3 inhibition. Following the company's Q4 earnings call, the analyst has increased confidence in a positive data readout in December. He raised his price target for the shares to $3.50 from 60c.
09/29/16
HCWC
09/29/16
DOWNGRADE
Target $1.5
HCWC
Neutral
Galectin Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded Galectin Therapeutics to Neutral after the company reported that the Phase 2 NASH-FX trial missed its primary endpoint. The analyst cut his price target for the shares to $1.50 from $8. He has "increased doubts about the true therapeutic effect of GR-MD-02 on fibrosis or cirrhosis."
GILD Gilead
$65.93

-0.57 (-0.86%)

03/20/17
JEFF
03/20/17
NO CHANGE
JEFF
Buy
Jefferies uncovers 'unnoticed' positive NASH data coming from Gilead
Jefferies analyst Brian Abrahams said his review of titles for the upcoming EASL meeting of the International Liver Congress appears to indicate that Gilead's ACC inhibitor GS-0976, which he calls "one of [the company's] least-talked-about assets in NASH," demonstrated significant positive effects in an as-yet-unreported phase 2 study. The analyst, who calls the presentation "unnoticed" and "not broadly discussed," believes the study may meaningfully de-risk a second NASH asset and could set the stage for increasing enthusiasm around Gilead's NASH program over the next 12 months. Abrahams keeps a Buy rating on Gilead shares. The ILC meeting is being held from April 19 to 23 in Amsterdam.
03/13/17
FBCO
03/13/17
NO CHANGE
Target $174
FBCO
Outperform
Incyte price target raised to $174 from $136 at Credit Suisse
Credit Suisse analyst Kennen MacKay raised his price target for Incyte (INCY) to $174 upon shifting to an M&A discounted cash flow net present value methodology. Incyte rallied late in the day on Friday amid speculation of a takeover by Gilead Sciences (GILD). Incyte could provide an attractive entry into immuno-oncology for an acquirer, MacKay tells investors in a research note. The company's epacadostat could be a "scarce immuno-oncology backbone blockbuster," the analyst contends. He anticipates "significant interest" in Incyte for this reason. MacKay keeps an Outperform rating on the shares.
03/09/17
UBSW
03/09/17
DOWNGRADE
Target $72
UBSW
Neutral
Gilead transferred with a Neutral from Buy at UBS
UBS downgraded Gilead Sciences to Neutral after transferring coverage to Carter Gould. The company's hepatitis C sales have declined steadily since 2015 on decreased patient volume and pricing pressure, Gould told investors last night in a research note. The analyst believes Gilead's HCV sales need to stabilize before the stock moves higher. He cut his firm's price target for the shares to $72 from $118.
04/21/17
PIPR
04/21/17
NO CHANGE
PIPR
Overweight
Piper Jaffray 'encouraged' by Gilead ACC inhibitor data in NASH
Piper Jaffray analyst Joshua Schimmer said Gilead's GS-0976 program in the treatment of NASH are the company's "most interesting" and the just announced data for the ACC inhibitor in a 10 patient study are very encouraging. The analyst, who continues to believe that reducing lipids is a key component for treating NASH, added that long term safety for inhibition of ACC will be necessary before he can have confidence in the program's potential. He keeps an Overweight rating on Gilead shares.
ICPT Intercept
$107.89

0.7 (0.65%)

02/23/17
FBCO
02/23/17
NO CHANGE
FBCO
Intercept shares defended at Credit Suisse
02/24/17
BMOC
02/24/17
NO CHANGE
BMOC
Intercept price target raised to $221 from $198 at BMO Capital
BMO Capital analyst M. Ian Somaiya raised his price target on Intercept as he believes that updated launch metrics on the company's Ocaliva drug suggest that 2017 sales of the product will exceed expectations. He keeps an Outperform rating on the stock.
02/28/17
SBSH
02/28/17
NO CHANGE
Target $240
SBSH
Buy
Intercept price target lowered to $240 from $275 at Citi
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $240 citing less upside potential over the next year with REGENERATE trial results still likely at least two years away. The analyst reiterates a Buy rating on Intercept, however, saying investors should get more comfortable that NASH is a "sizeable drug opportunity" as development of OCA and other NASH drugs advance.
02/10/17
MSCO
02/10/17
NO CHANGE
Target $75
MSCO
Underweight
Intercept price target lowered ot $75 from $80 at Morgan Stanley
Morgan Stanley analyst Andrew Berens said the changes to the RENGENERATE trial lower the bar and increase the probability of success but also reduce the prospect of a differentiated label. Berens said the amended trial design reduces the likelihood of Ocaliva emerging with a best-in-class status of fibrosis benefit and the slow enrollment suggests larger issues with NASH market development and challenges cultivating the NASH market commercially. The analyst lowered his price target on Intercept to $75 and reiterated his Underweight rating on Intercept shares.
JWA John Wiley & Sons; also tag JWB

NVS Novartis
$73.40

-0.22 (-0.30%)

04/21/17
ROTH
04/21/17
NO CHANGE
Target $12
ROTH
Buy
Conatus price target raised to $12 from $4 at Roth Capital
Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.
04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.
04/05/17
04/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Neutral from Buy at UBS. 2. Novartis (NVS) downgraded to Market Perform from Outperform at Cowen with analyst Steve Scala saying he believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout. 3. MSG Networks (MSGN) downgraded to Neutral following NY Post report at Macquarie with analyst Tim Nollen citing valuation and maintained its $26 price target. 4. Generac (GNRC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing concerns that increased pricing incentives and normalizing storm activity are impacting the growth for the company's Residential home standby business. 5. Amgen (AMGN) downgraded to Hold from Buy at Jefferies with analyst Eun Yang saying she believes upside in the stock will likely be "muted" after her payor poll indicated continuing reimbursement challenges for Repatha, Amgen's PCSK9 inhibitor to treat high cholesterol. Yang also sees a "scarcity of blockbuster potential pipeline products" and feels a transformative acquisition is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/17
COWN
04/05/17
DOWNGRADE
Target $77
COWN
Market Perform
Novartis downgraded to Market Perform from Outperform at Cowen
Cowen analyst Steve Scala downgraded Novartis to Market Perform and lowered his price target for the shares to $77 from $87. The analyst believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout.
OSUR OraSure
$12.67

0.03 (0.24%)

04/06/17
RAJA
04/06/17
NO CHANGE
RAJA
Outperform
Raymond James says 23andMe FDA approval bodes well OraSure
Raymond James analyst Nicholas Jansen said the FDA announced it would allow 23andMe to market Genetic Health Risk, or GHR tests for 10 diseases or conditions. OraSure is the provider of the collections device through its subsidiary DNA Genotek, and the analyst views this new development to be a clear positive. Jansen said the approval will reaccelerate the growth rate ahead of growing consumer awareness and reiterates his Outperform rating OraSure shares.
02/09/17
ADAM
02/09/17
NO CHANGE
Target $12
ADAM
Buy
OraSure set up for growth in 2017 and beyond, says Canaccord
Canaccord analyst Mark Massaro noted OraSure delivered solid Q4 results and gave good guidance for 2017. He said ongoing positive developments from its HCV business coupled with strong traction from its DNA Genotek business set it up for growth in 2017 and beyond. Massaro reiterated his Buy rating and raised his price target to $12 from $11 on OraSure shares. This note corrects an earlier version with an incorrect price target.
02/09/17
RAJA
02/09/17
UPGRADE
Target $11.25
RAJA
Outperform
OraSure upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Nicholas Jansen upgraded OraSure to Outperform with a $11.25 price target following the solid Q4 report and visible revenue catalysts over the next year that should move estimates higher. The analyst sees multiple international opportunities and tailwinds in DNA Genotek that support a more positive top-line trajectory and operating expense levers for robust underlying margin and free cash flow growth combined iwth recent restructuring actions and the wind down of legal costs. Jansen sees upside to his model in 2018 from additional HCV eradication work that is stripped out of our forecasts, new royalties tied to their ancestry.com settlement and the company's global manufacturing optimization program, which could further drive profitability.
12/20/16
KING
12/20/16
INITIATION
Target $11
KING
Buy
OraSure initiated with a Buy at CL King
CL King initiated OraSure with a Buy and a $11 price target.
SIEGY Siemens
$67.34

-0.197 (-0.29%)

05/27/16
JPMS
05/27/16
NO CHANGE
Target $27
JPMS
Underweight
JPMorgan recommends pair trade of long Siemens, short GE
JPMorgan analyst C. Stephen Tusa recommends a Global Industrials pair trade of log Siemens (SIEGY), short General Electric (GE). The analyst has an Underweight rating on GE with a $27 price target and a Neutral rating on Siemens. GE now trades at premium to Siemens while its earnings risk versus consensus will increase over the coming years, Tusa tells investors in a research note.
01/10/17
UBSW
01/10/17
UPGRADE
UBSW
Buy
Siemens upgraded to Buy from Neutral at UBS
01/11/17
GSCO
01/11/17
DOWNGRADE
GSCO
Sell
Siemens downgraded to Sell from Buy at Goldman
Goldman Sachs analyst Daniela Costa double downgraded Siemens to Sell from Buy and lowered her price target for the shares to EUR 100 from EUR 118.
09/07/16
UBSW
09/07/16
DOWNGRADE
UBSW
Neutral
Siemens downgraded to Neutral from Buy at UBS
UBS downgraded Siemens to Neutral saying the risk/reward is not attractive enough at current valuation levels.
VTL Vital Therapies
$3.50

-0.1 (-2.78%)

ARWR Arrowhead
$1.52

0.01 (0.66%)

11/30/16
11/30/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 2. Arrowhead (ARWR) was downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Buy at Chardan, to Hold from Buy at Cantor, and to Market Perform from Outperform at William Blair. 3. W.R. Grace (GRA) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander noting the potential for a sharp drop in free cash flow conversion once its net operating loss carry-forwards are exploited. 4. Abaxis (ABAX) downgraded to Neutral from Buy at Northcoast. 5. Duluth Holdings (DLTH) downgraded to Neutral from Outperform at Baird with analyst Jonathan Komp citing the stock's recent rally and the possibility its valuation metrics have pushed beyond the levels he believes it can sustain. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/03/17
WBLR
03/03/17
NO CHANGE
WBLR
HBV space to consolidate over next five years, says William Blair
William Blair analyst Y. Katherine Xu sees curing chronic hepatitis B virus infections as "the next frontier" after the success of hepatitis C treatments and believes the market for an HBV cure could be "similar in size to that of HCV," or $200B in cumulative global sales over a span of two decades. She expects consolidation of the HBV market over the next five years, much like what happened with the HCV market. Xu sees Spring Bank Pharmaceuticals (SBPH) and Arbutus (ABUS) as having the strongest data catalysts in 2017, followed by Assembly Biosciences (ASMB) and Arrowhead (ARWR). She has Outperform ratings on the first three stocks and a Market Perform rating on Arrowhead.
11/30/16
11/30/16
DOWNGRADE
Target $2

Market Perform
Arrowhead downgraded at William Blair after clinical programs discontinued
As previously reported, William Blair analyst Katherine Xu downgraded Arrowhead to Market Perform from Outperform after the company announced that it would discontinue all of its current clinical-stage programs three weeks after the FDA placed lead asset ARC-520 for hepatitis B virus on clinical hold. The company plans to shift focus to its preclinical subcutaneous and extra-hepatic RNAi platforms, though Xu estimates these programs are at least one to two years away from entering the clinic. Xu cut her price target on Arrowhead shares to $2 from $12.
11/30/16
CHDN
11/30/16
UPGRADE
CHDN
Buy
Arbutus Biopharma upgraded on competitor withdrawal at Chardan
As noted earlier, Chardan upgraded Arbutus (ABUS) to Buy from Neutral. Analyst Gbola Amusa upgraded the stock after Arrowhead (ARWR) announced that it was terminating its intravenously delivered RNAi clinical programs ARC-520, ARC-521, and ARC-AAT. The analyst now expects Arbutus' share of the HBV RNAi to rise to 47.5% from 17.5%. Amusa does not expect Arbutus' treatments to cause the same safety problems as those of Arrowhead. Amusa is upbeat on Arbutus' lead asset, ARB-1467. Target to $4 from $3.

TODAY'S FREE FLY STORIES

KMX

CarMax

$68.84

0.17 (0.25%)

, FINL

Finish Line

$9.22

-0.21 (-2.23%)

20:25
09/21/17
09/21
20:25
09/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KMX

CarMax

$68.84

0.17 (0.25%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:47
09/21/17
09/21
18:47
09/21/17
18:47
Periodicals
HP Enterprise planning approximately 5,000 job cuts, Bloomberg reports »

In part of a broader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

RP

RealPage

$39.35

-0.1 (-0.25%)

18:41
09/21/17
09/21
18:41
09/21/17
18:41
Hot Stocks
RealPage expects $3M-$4M of renter's insurance claims from hurricanes »

RealPage announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:39
09/21/17
09/21
18:39
09/21/17
18:39
Periodicals
Breaking Periodicals news story on HP Enterprise »

HP Enterprise planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

YUM

Yum! Brands

$76.48

0.11 (0.14%)

18:37
09/21/17
09/21
18:37
09/21/17
18:37
Conference/Events
Yum! Brands management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MAR

Marriott

$107.57

-0.12 (-0.11%)

18:32
09/21/17
09/21
18:32
09/21/17
18:32
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ESPGY

Esprit Holdings

$1.21

0.018 (1.51%)

18:29
09/21/17
09/21
18:29
09/21/17
18:29
Conference/Events
Esprit Holdings management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BA

Boeing

$256.04

0.58 (0.23%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Hot Stocks
Boeing: Turkish Airlines announces intent to order 40 787-9 Dreamliners »

Boeing and Turkish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

M

Macy's

$21.16

-0.32 (-1.49%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Conference/Events
Macy's management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

TAHO

Tahoe Resources

$5.60

0.02 (0.36%)

18:12
09/21/17
09/21
18:12
09/21/17
18:12
Hot Stocks
Tahoe Resources raises 2017 gold operations view to 400K-500K »

Tahoe Resources updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$18.42

0.02 (0.11%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Conference/Events
Atkore management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

, TXN

Texas Instruments

$86.05

0.22 (0.26%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

TXN

Texas Instruments

$86.05

0.22 (0.26%)

PSDO

Presidio

$13.95

-0.06 (-0.43%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 21

    Sep

FTR

Frontier Communications

$11.69

-0.31 (-2.58%)

18:10
09/21/17
09/21
18:10
09/21/17
18:10
Hot Stocks
Frontier Communications operations in Florida return to near-normal levels »

Daily operations for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$10.66

-0.06 (-0.56%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Playa Hotels & Resorts reports no significant damage from Maria »

Playa Hotels &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Ascendis spikes higher after Versartis Velocity trial fails to meet endpoint »

Shares of Ascendis Pharma…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$103.90

-0.04 (-0.04%)

18:04
09/21/17
09/21
18:04
09/21/17
18:04
Hot Stocks
Celanese increases price of acetyl intermediates »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNOW

NOW Inc.

$12.98

0.1 (0.78%)

18:03
09/21/17
09/21
18:03
09/21/17
18:03
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

JOBS

51job

$58.50

0.01 (0.02%)

18:02
09/21/17
09/21
18:02
09/21/17
18:02
Hot Stocks
51job announces strategic investment in Lagou »

51job announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$43.63

0.17 (0.39%)

17:53
09/21/17
09/21
17:53
09/21/17
17:53
Conference/Events
Hess Corp. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

APC

Anadarko

$48.49

3.68 (8.21%)

17:43
09/21/17
09/21
17:43
09/21/17
17:43
Recommendations
Anadarko analyst commentary at MUFG »

Anadarko buyback a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

HCC

Warrior Met Coal

$23.28

-1.05 (-4.32%)

17:42
09/21/17
09/21
17:42
09/21/17
17:42
Hot Stocks
Warrior Met Coal receives favorable IRS private letter ruling »

Warrior Met Coal reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAA

MAA

$107.27

-0.03 (-0.03%)

17:35
09/21/17
09/21
17:35
09/21/17
17:35
Hot Stocks
MAA announces estimated impact of Hurricanes Irma and Harvey »

MAA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$280.42

0.38 (0.14%)

17:31
09/21/17
09/21
17:31
09/21/17
17:31
Hot Stocks
Northrop Grumman awarded $124.7M government contract »

Northrop Grumman Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$205.72

1.45 (0.71%)

17:29
09/21/17
09/21
17:29
09/21/17
17:29
Hot Stocks
General Dynamics Electric Boat awarded $5B government contract »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAN

Aaron's

$38.83

-0.39 (-0.99%)

17:19
09/21/17
09/21
17:19
09/21/17
17:19
Hot Stocks
Aaron's provides update on impact of Hurricane Irma »

Aaron's plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.